Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2017
Febeuary 9, 2017
Exchange where listed: TSE

Name of listed company: TERUMO CORPORATION(URL http://www.terumo.com/): 4543: Yutaro Shintaku, President and CEO: Atsuo Omagari, General Manager, Corporate Communication Dept.
: +81 / 3-6742-8550

Company code number
Representative:
Please address all communications toPhone

1. Consolidated Financial Highlights for the Nine Months Ended December 31, 2016
(From April 1, 2016 to December 31, 2016)(1) Consolidated operating results

Nine months ended December, 2016
Nine months ended December, 2015

(Notes: The amounts shown below ignore values of less than a million yen)

Net sales(Millions of yen)

374,394
395,991%

Operating income

Ordinary income(Millions of yen)

(Millions of yen)

58,904
64,115(5.5)
9.0(Notes) Comprehensive income: December 2016: 43,654 million yen (-1.1%)(Yen)

As of December 31, 2016
As of March 31, 2016

(Notes) Shareholders' equity:

December 2015: 44,141 million yen (-51.6%)%

31,822 (26.8)
43,484 30.1

(Yen)

87.67
115.31(2) Consolidated financial position(Millions of yen)%

52,204 (14.4)
60,977
3.9(8.1)
21.3

Net income per share,
fully diluted

Net income per share

Nine months ended December, 2016
Nine months ended December, 2015%

Profit attributable toowners of parent

81.79
107.87

Total assets

Equity ratio

Net assets(Millions of yen)

(Millions of yen)

1,063,766
901,685

December 31 2016: 540,493 million yen

Net assets per share
(Yen)

%

540,905
511,544

March 31, 2016: 511,252 million yen

1,489.09
1,408.53

50.8
56.7

2. Dividends
1st quarter

Year ended March, 2016
Year ending March, 2017
Year ending March, 2017 (forecast)(Notes) Revise of dividends forecast : None(Yen)

Cash dividends per share

2nd quarter3rd quarter

19.00
20.00

－－－－

(Yen)

(Yen)

4th quarter

(Yen)

Total

20.00

(Yen)

39.00

21.00

41.00

3. Consolidated Forecast for the Year Ending March, 2017 (From April 1, 2016 to March 31, 2017)
Net sales(Millions of yen)

Operating income%(Millions of yen)

Ordinary income%(Millions of yen)%

510,000
71,00062,000Year ending March, 2017
(2.9)
(13.1)(15.2)(Notes) Forecast for fiscal year ending March, 2017 which was announced on November 10, 2016 has been revised.

Profit attributable toowners of parent(Millions of yen)

47,500Net income per share%(6.3)(Assumed exchange rate for fiscal year ending March, 2017: USD1=JPY107, EUR1=JPY118)(Assumed exchange rate for fourth quarter ending March, 2017: USD1=JPY110, EUR1=JPY120)

Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on
projections made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results may differ from those
forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo,
fluctuations of foreign exchange rates, and state of competition.

1(Yen)

130.86

4. Financial Statements(1) Consolidated balance sheets

Amount(Assets)
I

Current assets

374,746%

41.5

Amount499,906

149,672

Inventories

96,454104,138

Other

10,621

10,058Noncurrent assets

521,657

Buildings and structures

65,207

104,426

Deferred tax assets
Allowance for doubtful accounts(1,390)

1 Property, plant and equipment

175,794

14,93657.9
19.5

54,362

Land

Other

10,628290,514Goodwill

143,707

Other

56,056

Customer relationships

25,63332.3

90,7503 Investments and other assets

55,348Investment securities, including investments inunconsolidated subsidiaries and affiliates

6.1

Other

14,186

Total assets

901,685

5,281

2

163,77131.0

77,02749,066

4.6

34,866

3,436

Deferred assets

11,379329,917
89,11837,724

Deferred tax assets

64,206

52.6

17.0

974

21,4172 Intangible assets

180,428

23,213881

Construction in progress(1,372)559,41255,022

23,297

Lease assets

264,156%47.0

107,988

14,963

Machinery, equipment and vehicles

III

As of December 31, 2016

Cash and deposits

Noteｓ and accounts receivable-trade

II(Millions of yen)

As of March 31, 2016

3,922

0.6

100.0

10,2774,447

1,063,766

0.4

100.0

(Millions of yen)

As of March 31, 2016
Amount(Liabilities)
I

Current liabilities

168,835

Notes and accounts payable-trade36,294

Short-term debt

Current portion of bonds payable

40,00040,000

56

20

156

1,446

Provision for bonuses

5,869

3,079

Notes and accounts payable-facilities

5,451

6,025

Other

51,057－

52,691170

Noncurrent liabilities

221,304

Bonds payable

115

147

24.6

－

Convertible bonds with subscription rights to shares
Long-term debt

265,560

30,000100,184

100,147286

283

58,873

Lease obligations

45,07950,166Retirement benefit liabilities

8,656

8,912

Other

7,925

16,45266

Asset retirement obligations

14230

Total liabilities

390,140

Shareholders' equity

445,178

Capital stock

38,716

Capital surplus

70

43.3

49.4

50,928Retained earnings

419,573

Accumulated other comprehensive income

66,074

Treasury stock(64,040)

Unrealized gains (losses) on available-for-sale securities,
net of taxes

7.3(13,403)

Stock subscription rights

Non-controlling interests

Total liabilities and net assets

3(64,004)
77,993

7.3

76,2950.0

511,54456.7

901,685

43.5

(99)

183
109

Total net assets

38,716

13,65063,182

Accumulated adjustments for retirement benefits, net of taxes

462,499

49.2

50,928(13)

Foreign currency translation adjustments

522,860

436,858

16,308Deferred gains (losses) on hedges, net of taxes

25.0

59,512

Deferred tax liabilities

Provision for directors' retirement benefits

24.2

17,571

9,778

Asset retirement obligations

IV36,046%

100,000

256

Provision for directors' bonusesIII

257,299

19,839Deferred tax liabilities

II

18.7

AmountCurrent portion of long-term debt

Income taxes payable

I%

61

Lease obligations

II

As of December 31, 2016

0.0

100.0

(11,852)
2680.0540,90550.8

144

1,063,766

0.0

100.0

(2) Consolidated statements of income(Millions of yen)

For the nine months ended

For the nine months ended

December 31, 2015

AmountINet sales

IIISelling, general and administrative expenses

IV

Non-operating income

II

Cost of sales

471

Dividends income
Equity in earnings of affiliates
Other

Non-operating expenses

54.2

205,283

54.8

1,979

169,11038.0

146,379

16.2
0.5

372

106

794

－

5,117

1.3

744

1,035

Foreign exchange losses

2,361

3,662－746

318

Equity in losses of affiliates

1,353

Ordinary income

Extraordinary income

Gain on sales of property, plant and equipment

4,813

Gain on sales of investment securities

776

Extraordinary expenses

Loss on disposal of property, plant and equipment

226

Impairment loss

Restructuring loss－

60,977

5,590

1,245

15.4

1.4

0.3

Income before income taxes－

VIII Income taxes
Current

22,140

Deffered(267)

ProfitLoss attributable to non-controlling interests42.2

52,204

13.9

7,657

2.0

44,621

11.9

31,744

8.5

0.4

885

2,082

74－
299

74

0.0

373

2,178
65,322
21,872

16.5

5.5

43,44911.0

43,48411.0(34)

Profit attributable to owners of parent

8,126

1,426

－－

Loss on valuation of other investments

15.7

421

1,019

Loss on valuation of investment securities

39.1

58,904

326

48

Other

45.2

202

113

Interest expenses

Loss on disposal of inventories

VII

214,64845.8

321

Sales discounts

VI

100.0

276

Royalty income

V374,394

64,115Interest income

%

100.0

150,532

Operating income%

395,991

181,343

Gross profit

December 31, 2016

Amount

(0.0)

4,805

15,195(2,318)

12,876(77)

31,8223.4(0.0)
8.5

(3) Consolidated statements of comprehensive incomeIIIProfit
Other comprehensive income
Valuation difference on available-for-sale securities, netof taxes
Deferred gains or losses on hedges, net of taxes
Foreign currency translation adjustments
Adjustments for retirement benefit
Share of other comprehensive income of associates
accounted for using equity method, net of taxes
Comprehensive income
Comprehensive income attributable to:
Owners of parent
Non-controlling interests

For the nine months ended
December 31, 2015
Amount(Millions of yen)
For the nine months ended
December 31, 2016
Amount43,449691

31,744
11,9091,725
11(1,655)
611(2)(2,657)(87)
13,102
1,551
44,141
44,181(40)

5

143,65443,742(88)

5. Segment Information[Reportable Segments](1) The Third Quarter of Fiscal Year Ended March 31, 2016

Sales and operating income:Sales to customer

Cardiac andVascularCompany(Millions of yen)

Reportable Segments
GeneralHospitalCompany

Blood
Management
Company

Subtotal

193,241

122,777

79,972395,991

Sales total

193,241

122,777

79,972

Segment income (loss)

46,43918,249382

Internal sales

Segment income (Excl. Amortization)
Segment income(%)(Excl. Amortization)－－

47,801
24.7－

18,24914,32714.9

17.9

Adjustment

Total

395,991－－

395,991－

80,378－395,991

65,072(956)

64,115

20.3

－

(956)

79,422
20.1

Notes: 1. The (956) million yen adjustment to segment income is the sum of (1,046) million yen for inventories and 90
million yen for others.
2. Segment income is adjusted to be consistent with operating income shown on the quarterly consolidated income
statement.
－(2) The Third Quarter of Fiscal Year Ending March 31, 2017

Sales and operating income:Sales to customer

Cardiac andVascularCompany(Millions of yen)

Reportable Segments

GeneralHospitalCompany

Blood
Management
Company

Subtotal

Adjustment

Total

186,570

118,979

68,692374,242152

374,394

Sales total

186,570

118,979

68,692374,242－152

374,394

Segment income (loss)

45,56017,785(1,924)

61,422(2,517)58,904

Internal sales

Segment income (Excl. Amortization)

Segment income(%)(Excl. Amortization)－

47,519－25.5－

17,785

10,283

14.9

15.0

－

75,58820.2(2,517)－73,07019.5

Notes: 1. The 152 million yen adjustment to Sales to customer is proceeds from temporary staffing that is not attributableto reportable segments.
2. The (2,517) million yen adjustment to segment income is the sum of 1,141 million yen for inventories and (3,659)
million yen for others.
3. Segment income is adjusted to be consistent with operating income shown on the quarterly consolidated incomestatement.

(Note) Main products belonging to each business segment
Business segments
Sub-segments

Interventional Systems (TIS)

Cardiac and Vascular Company

NeurovascularCV Systems
Vascular Graft
General Hospital ProductsGeneral Hospital CompanyD&D
DM and Consumer Healthcare

Blood Management Company－6－

Main products

Angiographic catheters, PTCA balloon catheters,Coronary stents, etc.
Neuro interventional coils, etc.

Oxygenators, Cardio-pulmonary bypass system,etc.
Artificial vascular grafts, Stent grafts

Solution sets, I.V.catheters, Infusion pumps,
Syringe pumps, Syringes, Needles, Bloodcollection tubes, etc.

Prefilled syringes, Pain management systems,
I.V.solutions, Nutritious food, CAPD systems,etc.
Blood glucose monitoring systems, Digital
thermometers, Blood pressure monitors, etc.

Blood bags, Automated blood collection system,
Automated blood component processing system,
Centrifugal apheresis system, Cell expansion
system, etc.